Ferreres J C, Figols J, Val-Bernal J F, Cardesa A, Cruz Sánchez F F
Department of Pathology, Marqués de Valdecilla University Hospital, Santander, Spain.
Histol Histopathol. 1996 Jan;11(1):35-9.
In 87 astrocytic gliomas the number of AgNORs/nucleus was retrospectively studied and data correlated with the histological type of the tumors and survival. All patients were treated by the same surgical team and with uniform criteria. Statistically significant differences (p < 0.01) were found in relation with the AgNOR averages among the histological types of tumors. A statistically significant linear correlation (p < 0.05) between the AgNOR values and survival of the patients was also found. Patients with mean AgNOR values higher than 2.23 and lower than 2.9 survived an average of 11.5 +/- 9.1 months vs. a survival in average of 24.4 +/- 34.1 months with mean AgNOR values under 2.23 (p < 0.05). Patients with AgNOR values higher than 2.9 survived, on average, 7.7 +/- 3.9 months. AgNOR counting in astrocytic gliomas is a reproducible, easy, quick method with prognostic value. AgNORs may be successfully applied in routine material to assess the growth potential of astrocytic gliomas.
对87例星形细胞瘤患者的核仁组成区嗜银蛋白(AgNORs)/细胞核数量进行回顾性研究,并将数据与肿瘤的组织学类型和生存期相关联。所有患者均由同一手术团队按照统一标准进行治疗。结果发现,不同组织学类型肿瘤的AgNOR平均数量存在统计学显著差异(p < 0.01)。同时还发现,AgNOR值与患者生存期之间存在统计学显著线性相关性(p < 0.05)。平均AgNOR值高于2.23且低于2.9的患者平均生存期为11.5 +/- 9.1个月,而平均AgNOR值低于2.23的患者平均生存期为24.4 +/- 34.1个月(p < 0.05)。AgNOR值高于2.9的患者平均生存期为7.7 +/- 3.9个月。星形细胞瘤中AgNOR计数是一种可重复、简便、快速且具有预后价值的方法。AgNORs可成功应用于常规材料中,以评估星形细胞瘤的生长潜能。